Siponimod

Switching from S1Ps or HETs to DRF: results from the EVOLVE-MS-1 study 3:08
Switching from S1Ps or HETs to DRF: results from the EVOLVE-MS-1 study
Barry Singer • 28 Feb 2023
S1P receptor modulators in the treatment of MS 5:43
S1P receptor modulators in the treatment of MS
Bruce Cree • 13 Jun 2022
Progressive MS treatment – what is next? 1:39
Progressive MS treatment – what is next?
Giancarlo Comi • 23 Mar 2022
Using DMTs beyond patients with active MS 3:14
Using DMTs beyond patients with active MS
Xavier Montalban • 29 Mar 2022
Differential efficacy of DMTs in patients with active and inactive MS 1:30
Differential efficacy of DMTs in patients with active and inactive MS
Xavier Montalban • 29 Mar 2022
Changes in the MS treatment landscape over the last 2 years 6:03
Changes in the MS treatment landscape over the last 2 years
Abhijit Chaudhuri • 22 Mar 2022
Tailoring treatment in MS with new S1P receptor modulators 1:01
Tailoring treatment in MS with new S1P receptor modulators
Jiwon Oh • 25 Feb 2022
Characterizing real-world outcomes among COVID-19 vaccinated patients with MS 2:07
Characterizing real-world outcomes among COVID-19 vaccinated patients with MS
Namita Tundia • 25 Feb 2022
Using virtual placebo to assess long-term effect of siponimod on disability progression in SPMS 3:57
Using virtual placebo to assess long-term effect of siponimod on disability progression in SPMS
Bruce Cree • 21 Oct 2021
Neuroregenerative agents in progressive multiple sclerosis 1:08
Neuroregenerative agents in progressive multiple sclerosis
Xavier Montalban • 23 Sep 2021
Current treatments for primary and secondary progressive multiple sclerosis 4:46
Current treatments for primary and secondary progressive multiple sclerosis
Xavier Montalban • 23 Sep 2021
Next steps in MS treatment: optimizing what we have 3:36
Next steps in MS treatment: optimizing what we have
Giancarlo Comi • 21 Jun 2021
Determining the optimal treatment strategy in MS 4:18
Determining the optimal treatment strategy in MS
Tanuja Chitnis • 23 Feb 2021
Treating MS: new therapies and COVID-19 3:23
Treating MS: new therapies and COVID-19
Abhijit Chaudhuri • 21 Oct 2020
The content of VJNeurology is intended for healthcare professionals